Sandoz International GmbH
www.sandoz.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Sandoz International GmbH
Sandoz Gets EU Nod For Higher-Strength Adalimumab
Sandoz has received a positive opinion from the EMA’s CHMP recommending that its high-concentration 100mg/ml adalimumab biosimilar be granted a pan-European marketing authorization. Three generics were also endorsed at the CHMP’s January meeting, including a rival to Forxiga.
Sandoz Adds To Anti-Infectives With Astellas Mycamine Deal
Sandoz and Astellas have struck a deal that will see the Novartis subsidiary acquire global rights to the Mycamine micafungin antifungal brand, bolstering Sandoz’s anti-infectives portfolio and hospital offering.
Who’s Hired? Firms Ring In 2023 With Fresh Faces
The start of 2023 has seen a number of firms across the off-patent industry announce management changes, with multiple appointments at Sandoz, a new CFO at Stada, a fresh CSO at Mallinckrodt, new generics leadership at Orion and board changes at Viatris and EuroAPI.
Sandoz Pushes Back On AMR And ‘Dysfunctional’ Antibiotics Market
Sandoz CEO Richard Saynor and global head of anti-infectives Ian Ball have spoken out on the threat of antimicrobial resistance and the “increasing dysfunctionality” of the market framework for antibiotics.
Company Information
- Industry
-
Pharmaceuticals
- Generic Drugs
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice